AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21058823 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trial (RCT)
Number of subjects: 0
Study 21058823 — intervention group
Group type: EXPERIMENTAL
Intervention: Other methods of inquiry
Number of subjects: 0
Study 17409317 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1428
Study 17409317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1428
Study 17409317 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (Losartan and Placebo)
Number of subjects: 1428
Study 17409317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SBP and albuminuria reduction
Number of subjects: 1428
Study 17409317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower residual level of albuminuria
Number of subjects: 1428
Study 17409317 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in albuminuria
Number of subjects: 1428
Study 17409317 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP or albuminuria reduction
Number of subjects: 1428
Study 16464424 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11806863 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of propranolol
Number of subjects: 38
Study 11806863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9726683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg q.d. for 14 days)
Number of subjects: 3413
Study 9726683 — intervention group
Group type: COMPARATOR
Intervention: No treatment (nasal saline drops allowed)
Number of subjects: 3413
Study 8039152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years
Number of subjects: 1600
Study 8039152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential tamoxifen/megestrol for 2 years
Number of subjects: 1600
Study 8039152 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy
Number of subjects: 1600
Study 8039152 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐dose chemotherapy+autologous bone marrow transplantation
Number of subjects: 1600
Study 8039152 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy to the breast
Number of subjects: 1600
Study 8039152 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF- or FEC-chemotherapy plus APD (pamidronate)
Number of subjects: 1600
Study 2743845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 7
Study 2743845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30793734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg with P2Y12 inhibitor
Number of subjects: 2725
Study 30793734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg with P2Y12 inhibitor
Number of subjects: 2725
Study 30793734 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran dual therapy
Number of subjects: 2725
Study 27655276 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal oxygenation via a modified 3.5‐mm Ring‐Adair‐Elwyn (RAE) tube
Number of subjects: 40
Study 27655276 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 25744196 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux hemodialysis (LF-HD)
Number of subjects: 31
Study 25744196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis (HF-HD)
Number of subjects: 31
Study 25744196 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 31
Study 23846588 — intervention group
Group type: EXPERIMENTAL
Intervention: Overcoming Addictions (OA) alone
Number of subjects: 189
Study 23846588 — intervention group
Group type: EXPERIMENTAL
Intervention: OA+attend SMART Recovery (SR) meetings (OA+SR)
Number of subjects: 189
Study 23846588 — intervention group
Group type: COMPARATOR
Intervention: Attend SMART Recovery (SR) only
Number of subjects: 189
Study 21327867 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss (DIWL)
Number of subjects: 16
Study 21327867 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX)
Number of subjects: 16
Study 19959920 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored intervention program consisting of physical and daily activities led by physiotherapists and occupational therapists for three months
Number of subjects: 322
Study 19959920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 322
Study 17303627 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation with combined lesions in the right and left atria
Number of subjects: 126
Study 17303627 — intervention group
Group type: COMPARATOR
Intervention: Best antiarrhythmic drug therapy
Number of subjects: 126
Study 15536458 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus aurantium
Number of subjects: 12
Study 15536458 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea
Number of subjects: 12
Study 15536458 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk thistle
Number of subjects: 12
Study 15536458 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto
Number of subjects: 12
Study 10678834 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of familiar stimuli (faces and symbols)
Number of subjects: 0
Study 10678834 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of unfamiliar stimuli
Number of subjects: 0
Study 10678834 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition effects with varying lag between presentations
Number of subjects: 0
Study 10678834 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple repetitions of stimuli
Number of subjects: 0
Study 9035428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 110
Study 9035428 — intervention group
Group type: COMPARATOR
Intervention: Petroleum jelly
Number of subjects: 110
Study 9035428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol and Petroleum jelly
Number of subjects: 110
Study 1540109 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste Aversion Group (CS1‐US‐CS2‐Test)
Number of subjects: 0
Study 1540109 — intervention group
Group type: EXPERIMENTAL
Intervention: Overshadowing Group (CS1‐CS2‐US‐Test)
Number of subjects: 0
Study 1540109 — intervention group
Group type: COMPARATOR
Intervention: Control Group (US‐CS1‐CS2‐Test)
Number of subjects: 0
Study 4039870 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular preparation
Number of subjects: 0
Study 4039870 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell pertussis vaccine
Number of subjects: 0
Study 4039870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 0
Study 31812284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 31812284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30946926 — intervention group
Group type: EXPERIMENTAL
Intervention: Countdown timer group (3000 ms constant foreperiod with a 1000 ms countdown timer)
Number of subjects: 36
Study 30946926 — intervention group
Group type: COMPARATOR
Intervention: Single key-press response
Number of subjects: 36
Study 30946926 — intervention group
Group type: COMPARATOR
Intervention: Three key-presses with equal/isochronous time interval
Number of subjects: 36
Study 30946926 — intervention group
Group type: COMPARATOR
Intervention: Three key-presses with unequal/non-isochronous time interval
Number of subjects: 36
Study 29454724 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent diabetes detected by OGTT
Number of subjects: 988
Study 29454724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diabetes detected by OGTT
Number of subjects: 988
Study 29454724 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose metabolism
Number of subjects: 988
Study 29454724 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent diabetes detected by glycosylated hemoglobin and fasting plasma glucose
Number of subjects: 988
Study 29454724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-diabetes detected by glycosylated hemoglobin and fasting plasma glucose
Number of subjects: 988
Study 29454724 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose metabolism (glycosylated hemoglobin and fasting plasma glucose)
Number of subjects: 988
Study 29454724 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal glucose metabolism (both diagnostic approaches)
Number of subjects: 988
Study 26926775 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin alone (550 mg twice daily for 3 months)
Number of subjects: 60
Study 26926775 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin in combination with lactulose (30-60 ml daily for 3 months)
Number of subjects: 60
Study 26926775 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60
Study 24738713 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 5 cm H2O + PSV 5 cm H2O (CPAP/PSV, n = 22)
Number of subjects: 44
Study 24738713 — intervention group
Group type: COMPARATOR
Intervention: Neutral-pressure breathing without CPAP/PSV (control, n = 22)
Number of subjects: 44
Study 21887685 — intervention group
Group type: COMPARATOR
Intervention: No bortezomib (Group 1)
Number of subjects: 60
Study 21887685 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m2 × 3 doses (Group 2)
Number of subjects: 60
Study 21887685 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.5 mg/m2 × 3 doses (Group 3)
Number of subjects: 60
Study 19091394 — intervention group
Group type: COMPARATOR
Intervention: Endocrine treatment alone (3 months of total androgen blockade followed by continuous endocrine treatment using flutamide)
Number of subjects: 875
Study 19091394 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment plus radiotherapy
Number of subjects: 875
Study 19091394 — intervention group
Group type: COMPARATOR
Intervention: Endocrine treatment alone
Number of subjects: 875
Study 18158693 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to land softer
Number of subjects: 25
Study 18158693 — intervention group
Group type: COMPARATOR
Intervention: No instructions (control group)
Number of subjects: 25
Study 15149346 — intervention group
Group type: COMPARATOR
Intervention: High flux dialysis
Number of subjects: 1846
Study 15149346 — intervention group
Group type: COMPARATOR
Intervention: High dose dialysis
Number of subjects: 1846
Study 15149346 — intervention group
Group type: COMPARATOR
Intervention: Standard dose dialysis
Number of subjects: 1846
Study 15149346 — intervention group
Group type: EXPERIMENTAL
Intervention: All randomized groups
Number of subjects: 1846
Study 12696398 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 98
Study 12696398 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (SP)
Number of subjects: 98
Study 10690147 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex Soft Seal tube cuff
Number of subjects: 0
Study 10690147 — intervention group
Group type: COMPARATOR
Intervention: Mallinckrodt Lo‐Contour tube cuff
Number of subjects: 0
Study 10690147 — intervention group
Group type: COMPARATOR
Intervention: Portex Profile tube cuff
Number of subjects: 0
Study 8917264 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐beta‐estradiol patches (100 micrograms/24 h)
Number of subjects: 25
Study 8917264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2060286 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 30
Study 2060286 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 30
Study 2060286 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate/fentanyl
Number of subjects: 30
Study 2060286 — intervention group
Group type: EXPERIMENTAL
Intervention: multiparametric methods
Number of subjects: 30
Study 2060286 — intervention group
Group type: COMPARATOR
Intervention: single parametric methods
Number of subjects: 30
Study 6837016 — intervention group
Group type: EXPERIMENTAL
Intervention: Internists
Number of subjects: 0
Study 6837016 — intervention group
Group type: COMPARATOR
Intervention: Family practitioners
Number of subjects: 0
Study 6837016 — intervention group
Group type: COMPARATOR
Intervention: Laboratory tests ordered by family practitioners
Number of subjects: 0
Study 3885664 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (1 g) intravenous metronidazole prophylaxis
Number of subjects: 0
Study 3885664 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis and doxycycline therapy in case of perforation
Number of subjects: 0
Study 3885664 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls for unperforated appendix
Number of subjects: 0
Study 30695291 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 1522
Study 30695291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion augmentation
Number of subjects: 1522
Study 30695291 — intervention group
Group type: COMPARATOR
Intervention: Switching to bupropion
Number of subjects: 1522
Study 26816605 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-driven titration of BIAsp 30 BID
Number of subjects: 344
Study 26816605 — intervention group
Group type: COMPARATOR
Intervention: Investigator-driven titration of BIAsp 30 BID
Number of subjects: 344
Study 25337749 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide followed by 4 months of daily isoniazid and rifampicin)
Number of subjects: 827
Study 25337749 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month regimen (daily moxifloxacin for 2 months followed by weekly moxifloxacin and 1200 mg rifapentine for 4 months)
Number of subjects: 827
Study 25337749 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month regimen (daily moxifloxacin for 2 months followed by moxifloxacin and 900 mg rifapentine twice weekly for 2 months)
Number of subjects: 827
Study 23538567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low educational status (4 to 10 years) in PD group
Number of subjects: 28
Study 23538567 — intervention group
Group type: EXPERIMENTAL
Intervention: High educational status (≥11 years) in PD group
Number of subjects: 28
Study 23538567 — intervention group
Group type: COMPARATOR
Intervention: Low educational status (4 to 10 years) in control group
Number of subjects: 28
Study 23538567 — intervention group
Group type: COMPARATOR
Intervention: High educational status (≥11 years) in control group
Number of subjects: 28
Study 19935072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group US)
Number of subjects: 60
Study 19935072 — intervention group
Group type: COMPARATOR
Intervention: Surface anatomy guidance (group SA)
Number of subjects: 60
Study 17426742 — intervention group
Group type: EXPERIMENTAL
Intervention: Muesli with 4 g beta-glucans
Number of subjects: 32
Study 17426742 — intervention group
Group type: COMPARATOR
Intervention: Muesli with 3 g beta-glucans
Number of subjects: 32
Study 17426742 — intervention group
Group type: COMPARATOR
Intervention: Reference meal without beta-glucans
Number of subjects: 32
Study 17127465 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown rice
Number of subjects: 19
Study 17127465 — intervention group
Group type: COMPARATOR
Intervention: Milled rice
Number of subjects: 19
Study 14607575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sibutramine (10 mg/day)
Number of subjects: 40
Study 14607575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral EE‐CPA (35 microg‐2 mg/day)
Number of subjects: 40
Study 14607575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EE‐CPA plus sibutramine
Number of subjects: 40
Study 11004041 — intervention group
Group type: EXPERIMENTAL
Intervention: IHNB-MAC
Number of subjects: 81
Study 11004041 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 81
Study 11004041 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 81
Study 8848411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 28
Study 8848411 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 28
Study 1633069 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid micellar solution
Number of subjects: 12
Study 1633069 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster releasing microemulsion formulation
Number of subjects: 12
Study 1633069 — intervention group
Group type: COMPARATOR
Intervention: Standard soft gelatine preparation
Number of subjects: 12
Study 6425910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 122
Study 6425910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 122
Study 6425910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 30678657 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants associated with postoperative complications
Number of subjects: 1170
Study 30678657 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset of atrial fibrillation, delirium, myocardial infarction, acute kidney injury and stroke
Number of subjects: 1170
Study 29501739 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise intervention for six months
Number of subjects: 254
Study 29501739 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 254
Study 27185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine pressurized metered dose inhaler (pMDI) plus active nicotine patch
Number of subjects: 502
Study 27185903 — intervention group
Group type: COMPARATOR
Intervention: Placebo pMDI plus active nicotine patch
Number of subjects: 502
Study 24630572 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid group (n=50)
Number of subjects: 100
Study 24630572 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 100
Study 22919348 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) with conventional medical treatment, 10 sessions within 3-5 days after stroke onset.
Number of subjects: 46
Study 22919348 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment without HBOT.
Number of subjects: 46
Study 22919348 — intervention group
Group type: COMPARATOR
Intervention: Comparison of changes in NIHSS scores between HBOT and control groups.
Number of subjects: 46
Study 20200258 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 home-delivered therapeutic DASH meals per week for 12 months
Number of subjects: 298
Study 17665483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for 24 weeks
Number of subjects: 315
Study 17665483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 16096124 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment
Number of subjects: 122
Study 16096124 — intervention group
Group type: COMPARATOR
Intervention: Non-preferred treatment
Number of subjects: 122
Study 12394705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sacral neuromodulation
Number of subjects: 33
Study 12394705 — intervention group
Group type: COMPARATOR
Intervention: Unilateral sacral neuromodulation
Number of subjects: 33
Study 9464714 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and conjugated equine estrogens 0.625 mg daily (Group C)
Number of subjects: 201
Study 9464714 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and conjugated equine estrogens 1.25 mg daily (Group D)
Number of subjects: 201
Study 9464714 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + placebos for progestin and estrogen (Group A)
Number of subjects: 201
Study 9464714 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and placebo for estrogen (Group B)
Number of subjects: 201
Study 9464714 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg and conjugated equine estrogens 0.625 mg daily (Group C)
Number of subjects: 201
Study 9464714 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg daily (Group D)
Number of subjects: 201
Study 7589597 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body PET with FDG
Number of subjects: 76
Study 7589597 — intervention group
Group type: COMPARATOR
Intervention: Routine imaging (CT pelvis, CT/US liver and CXR)
Number of subjects: 76
Study 2773686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen administered continuously via programmable pump (90 to 150 micrograms per day)
Number of subjects: 14
Study 2773686 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine single injection
Number of subjects: 14
Study 2773686 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen bolus injection (30 to 60 micrograms)
Number of subjects: 14
Study 907460 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid resuscitation
Number of subjects: 20
Study 907460 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid resuscitation
Number of subjects: 20
Study 907460 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid and colloid resuscitation
Number of subjects: 20
Study 31563866 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-and-extend ranibizumab (T&E)
Number of subjects: 529
Study 31563866 — intervention group
Group type: COMPARATOR
Intervention: Monthly ranibizumab
Number of subjects: 529
Study 30572163 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care intervention (12 weeks)
Number of subjects: 100
Study 30572163 — intervention group
Group type: COMPARATOR
Intervention: Attention Control condition (12 weeks)
Number of subjects: 100
Study 28127849 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (brief lecture and training exercise)
Number of subjects: 120
Study 28127849 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (only lecture)
Number of subjects: 120
Study 28127849 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (only training exercise)
Number of subjects: 120
Study 28127849 — intervention group
Group type: COMPARATOR
Intervention: Group 4 (control group, no intervention)
Number of subjects: 120